Travere Therapeutics (TVTX) Net Cash Flow (2011 - 2026)

Travere Therapeutics has reported Net Cash Flow for 16 years, with the latest figure at -$14.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 619.3% year-over-year to -$14.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.8 million (down 43.29% YoY), and the FY2025 full-year result was $32.2 million, up 269.24% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$14.6 million, up from -$17.5 million in the prior quarter.
• The five-year high for Net Cash Flow was $91.8 million in Q1 2022, with the low at -$288.6 million in Q4 2023.
• Historically, Net Cash Flow has averaged -$23.8 million across 5 years, with a median of -$11.0 million in 2024.
• Annual changes were most pronounced in 2025 — Net Cash Flow soared 870.5% — and 2026, when it sank 619.3%.
• Travere Therapeutics' Net Cash Flow stood at -$112.2 million in 2022, then slumped by 157.11% to -$288.6 million in 2023, then jumped by 110.58% to $30.5 million in 2024, then sank by 157.24% to -$17.5 million in 2025, then climbed by 16.41% to -$14.6 million in 2026.
• The last three Net Cash Flow figures came in at -$14.6 million (Q1 2026), -$17.5 million (Q4 2025), and $35.6 million (Q3 2025), per Business Quant data.